Uterine Sarcoma: Analysis of 13,089 Cases Based on Surveillance, Epidemiology, and End Results Database
The aim was to study the incidence and survival of patients with uterine sarcoma diagnosed in the period from 2000 to 2012 based on Surveillance, Epidemiology, and End Results (SEER) database. All 18 registries of the SEER database were used to select cases. We included women aged 30 years or older...
Saved in:
Published in | International journal of gynecological cancer Vol. 26; no. 6; pp. 1098 - 1104 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BMJ Publishing Group LTD
01.07.2016
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The aim was to study the incidence and survival of patients with uterine sarcoma diagnosed in the period from 2000 to 2012 based on Surveillance, Epidemiology, and End Results (SEER) database.
All 18 registries of the SEER database were used to select cases. We included women aged 30 years or older diagnosed with uterine sarcoma. Histological subtypes were defined as leiomyosarcoma, carcinosarcoma, stromal sarcoma, adenosarcoma, and sarcoma not otherwise specified according to the 2003 World Health Organization classification. Using SEER*Stat software version 8.1.2. We calculated the age-adjusted incidence rates, extent of disease at time of diagnosis, and survival rates with different treatment modalities for white, black, and other races. Univariate and multivariate Cox proportional hazards analysis were done to examine factors affecting survival.
We identified 13,089 patients diagnosed with uterine sarcoma in the period from 2000 to 2012. The age-adjusted incidence rate for patients aged 50 years or older was more than that of younger patients (6.4/10 vs 1.5/10, P < 0.0001). Also, the age-adjusted incidence rate for black women was twice that of white women (7.3/10 vs 3.5/10, P < 0.0001). Carcinosarcoma was the most commonly diagnosed subtype followed by leiomyosarcoma. Women aged 50 years or older had worse survival than those younger than 50 years (hazard ratio, 1.78; 95% confidence interval, 1.64-1.92; P < 0.001). The overall survival of patients who had surgery with radiation was better than those who had surgery alone (hazard ratio, 0.89; 95% confidence interval, 0.83-0.95; P < 0.001). In women with localized disease, surgery was associated with better survival than surgery with radiation (66.4% vs 74.4%, P < 0.00001).
Uterine sarcoma is an aggressive tumor that occurs more in old age and among women of black race. Poor survival was associated with old age, black race, and advanced disease stage. Radiotherapy in patients with localized stage does not improve the survival. |
---|---|
AbstractList | ObjectiveThe aim was to study the incidence and survival of patients with uterine sarcoma diagnosed in the period from 2000 to 2012 based on Surveillance, Epidemiology, and End Results (SEER) database.MethodsAll 18 registries of the SEER database were used to select cases. We included women aged 30 years or older diagnosed with uterine sarcoma. Histological subtypes were defined as leiomyosarcoma, carcinosarcoma, stromal sarcoma, adenosarcoma, and sarcoma not otherwise specified according to the 2003 World Health Organization classification. Using SEER*Stat software version 8.1.2. We calculated the age-adjusted incidence rates, extent of disease at time of diagnosis, and survival rates with different treatment modalities for white, black, and other races. Univariate and multivariate Cox proportional hazards analysis were done to examine factors affecting survival.ResultsWe identified 13,089 patients diagnosed with uterine sarcoma in the period from 2000 to 2012. The age-adjusted incidence rate for patients aged 50 years or older was more than that of younger patients (6.4/105 vs 1.5/105, P < 0.0001). Also, the age-adjusted incidence rate for black women was twice that of white women (7.3/105 vs 3.5/105, P < 0.0001). Carcinosarcoma was the most commonly diagnosed subtype followed by leiomyosarcoma. Women aged 50 years or older had worse survival than those younger than 50 years (hazard ratio, 1.78; 95% confidence interval, 1.64–1.92; P < 0.001). The overall survival of patients who had surgery with radiation was better than those who had surgery alone (hazard ratio, 0.89; 95% confidence interval, 0.83–0.95; P < 0.001). In women with localized disease, surgery was associated with better survival than surgery with radiation (66.4% vs 74.4%, P < 0.00001).ConclusionsUterine sarcoma is an aggressive tumor that occurs more in old age and among women of black race. Poor survival was associated with old age, black race, and advanced disease stage. Radiotherapy in patients with localized stage does not improve the survival. The aim was to study the incidence and survival of patients with uterine sarcoma diagnosed in the period from 2000 to 2012 based on Surveillance, Epidemiology, and End Results (SEER) database. All 18 registries of the SEER database were used to select cases. We included women aged 30 years or older diagnosed with uterine sarcoma. Histological subtypes were defined as leiomyosarcoma, carcinosarcoma, stromal sarcoma, adenosarcoma, and sarcoma not otherwise specified according to the 2003 World Health Organization classification. Using SEER*Stat software version 8.1.2. We calculated the age-adjusted incidence rates, extent of disease at time of diagnosis, and survival rates with different treatment modalities for white, black, and other races. Univariate and multivariate Cox proportional hazards analysis were done to examine factors affecting survival. We identified 13,089 patients diagnosed with uterine sarcoma in the period from 2000 to 2012. The age-adjusted incidence rate for patients aged 50 years or older was more than that of younger patients (6.4/10 vs 1.5/10, P < 0.0001). Also, the age-adjusted incidence rate for black women was twice that of white women (7.3/10 vs 3.5/10, P < 0.0001). Carcinosarcoma was the most commonly diagnosed subtype followed by leiomyosarcoma. Women aged 50 years or older had worse survival than those younger than 50 years (hazard ratio, 1.78; 95% confidence interval, 1.64-1.92; P < 0.001). The overall survival of patients who had surgery with radiation was better than those who had surgery alone (hazard ratio, 0.89; 95% confidence interval, 0.83-0.95; P < 0.001). In women with localized disease, surgery was associated with better survival than surgery with radiation (66.4% vs 74.4%, P < 0.00001). Uterine sarcoma is an aggressive tumor that occurs more in old age and among women of black race. Poor survival was associated with old age, black race, and advanced disease stage. Radiotherapy in patients with localized stage does not improve the survival. |
Author | Antar, Sarah Warda, Mahmoud Gibreel, Ahmed Nazzal, Ahmed Refky, Basel Hosh, Mona |
Author_xml | – sequence: 1 givenname: Mona surname: Hosh fullname: Hosh, Mona organization: Mansoura University Hospital; †Obstetrics and Gynecology Department, Mansoura University, Mansoura, Egypt, and ‡Oncology Center, Mansoura University, Mansoura, Egypt – sequence: 2 givenname: Sarah surname: Antar fullname: Antar, Sarah – sequence: 3 givenname: Ahmed surname: Nazzal fullname: Nazzal, Ahmed – sequence: 4 givenname: Mahmoud surname: Warda fullname: Warda, Mahmoud – sequence: 5 givenname: Ahmed surname: Gibreel fullname: Gibreel, Ahmed – sequence: 6 givenname: Basel surname: Refky fullname: Refky, Basel |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27177280$$D View this record in MEDLINE/PubMed |
BookMark | eNpNkF9LwzAUxYNM3B_9BiIBX9eZmzZN4ttW5xwMBOfAt5I06ehom9m0wr69FSd44dx7H373wLljNKhdbRG6BTIDIvnDepXMyP_ilFygETDKAohCMeh3EolASPgYorH3h56RlMgrNKQcOKeCjNB-19qmqC3eqiZzlXrE81qVJ1947HIM4ZQIiRPlrceLvhvsarztmi9blKWqMzvFy2NhbFW40u1PU6xqg5e93qzvytbjJ9Uq3R9eo8tcld7enOcE7Z6X78lLsHldrZP5JsgiRkgAJiM5k4xyEeUaZGxyanIwlGnQOqdKaRoZHrJMSgVUE0EF1wC8j2_iDMIJuv_1PTbus7O-TQ-ua_pIPqWMSyLimP9Qd2eq05U16bEpKtWc0r-_hN9vEWUB |
CitedBy_id | crossref_primary_10_3389_fonc_2024_1354032 crossref_primary_10_1200_JCO_21_02050 crossref_primary_10_2147_CMAR_S267128 crossref_primary_10_3389_fsurg_2022_985654 crossref_primary_10_1038_s41379_022_01011_z crossref_primary_10_1007_s13669_017_0197_z crossref_primary_10_3390_clinpract11040103 crossref_primary_10_1186_s12905_022_02077_2 crossref_primary_10_1111_jog_13695 crossref_primary_10_1186_s12905_022_01739_5 crossref_primary_10_1007_s43032_021_00731_y crossref_primary_10_1186_s12885_023_11000_3 crossref_primary_10_1007_s00261_021_03263_w crossref_primary_10_3802_jgo_2020_31_e25 crossref_primary_10_1186_s12885_019_5879_7 crossref_primary_10_1007_s00432_023_04594_5 crossref_primary_10_1097_MD_0000000000025309 crossref_primary_10_1097_JCMA_0000000000000188 crossref_primary_10_1016_j_gore_2023_101308 crossref_primary_10_3389_fonc_2020_623818 crossref_primary_10_1080_14656566_2019_1571042 crossref_primary_10_1016_j_jogc_2018_02_005 crossref_primary_10_1136_ijgc_2020_001409 crossref_primary_10_1002_cam4_2044 crossref_primary_10_1097_GCO_0000000000000551 crossref_primary_10_1016_j_ygyno_2017_06_018 crossref_primary_10_2298_VSP230901063S crossref_primary_10_5180_jsgoe_37_1_135 crossref_primary_10_1016_S1283_081X_19_42006_7 crossref_primary_10_21802_artm_2024_2_30_31 crossref_primary_10_1002_ccr3_1491 crossref_primary_10_1053_j_sult_2019_03_004 crossref_primary_10_1097_PGP_0000000000000918 crossref_primary_10_1200_JCO_19_00151 crossref_primary_10_3389_fonc_2020_608152 crossref_primary_10_1016_j_ygyno_2019_08_033 crossref_primary_10_1016_j_critrevonc_2017_12_009 crossref_primary_10_2214_AJR_24_31280 crossref_primary_10_1148_rg_220161 crossref_primary_10_1186_s13046_023_02687_0 crossref_primary_10_1016_j_ejso_2017_08_011 crossref_primary_10_1016_j_jogc_2017_03_090 crossref_primary_10_1007_s00404_023_07057_x crossref_primary_10_1111_1471_0528_14579 crossref_primary_10_1245_s10434_023_13826_4 crossref_primary_10_5005_jp_journals_10006_2078 crossref_primary_10_1016_j_jogoh_2019_101631 crossref_primary_10_1016_j_ygyno_2018_10_034 crossref_primary_10_3390_jpm13060985 crossref_primary_10_1002_cac2_12067 crossref_primary_10_1097_IGC_0000000000000911 crossref_primary_10_1186_s13000_024_01517_x crossref_primary_10_1002_uog_20270 crossref_primary_10_1002_cam4_4643 crossref_primary_10_1007_s00404_022_06515_2 crossref_primary_10_1016_j_crad_2020_11_115 crossref_primary_10_1097_MD_0000000000010268 crossref_primary_10_22159_ajpcr_2023_v16i2_46205 crossref_primary_10_1097_IGC_0000000000001289 crossref_primary_10_1016_j_ejogrb_2017_06_029 crossref_primary_10_1016_j_phymed_2018_12_029 crossref_primary_10_1097_AOG_0000000000004711 crossref_primary_10_1186_s12885_022_10129_x crossref_primary_10_1111_his_14870 crossref_primary_10_3390_cimb45080390 crossref_primary_10_1007_s13224_021_01612_9 crossref_primary_10_21802_artm_2023_3_27_36 crossref_primary_10_1016_j_ygyno_2021_05_003 crossref_primary_10_1155_2020_8973262 crossref_primary_10_1016_j_ijscr_2022_107163 crossref_primary_10_1016_j_pathol_2017_11_086 crossref_primary_10_1053_j_semdp_2022_01_004 crossref_primary_10_1016_j_gore_2022_100980 crossref_primary_10_1097_MD_0000000000028220 crossref_primary_10_3892_mco_2021_2400 crossref_primary_10_5468_ogs_2019_62_2_103 crossref_primary_10_1080_01443615_2020_1803238 crossref_primary_10_1002_jcla_24502 crossref_primary_10_3390_cancers14061561 crossref_primary_10_28982_josam_878243 crossref_primary_10_1016_j_ejogrb_2017_10_030 crossref_primary_10_1148_radiol_211658 crossref_primary_10_1002_cam4_4665 crossref_primary_10_1186_s12955_022_01971_5 crossref_primary_10_1007_s13224_018_1141_5 crossref_primary_10_1371_journal_pone_0271526 crossref_primary_10_1007_s00292_022_01072_6 crossref_primary_10_1186_s12905_023_02161_1 crossref_primary_10_1007_s40944_018_0247_0 crossref_primary_10_1016_j_ajog_2018_11_1086 crossref_primary_10_1159_000494225 crossref_primary_10_1210_endrev_bnab039 crossref_primary_10_1177_15330338241245924 crossref_primary_10_1016_j_ijsu_2018_03_075 crossref_primary_10_1111_jog_14514 crossref_primary_10_1016_j_mcna_2022_10_010 crossref_primary_10_3390_cancers11101590 crossref_primary_10_1016_j_ygyno_2021_09_010 crossref_primary_10_1136_ijgc_2022_003383 crossref_primary_10_25259_SNI_621_2020 crossref_primary_10_3390_diagnostics14020160 crossref_primary_10_1136_bcr_2023_257228 crossref_primary_10_3390_cancers12082126 crossref_primary_10_1097_PPO_0000000000000678 crossref_primary_10_1007_s13691_021_00493_z crossref_primary_10_1016_j_maturitas_2021_09_001 crossref_primary_10_1159_000494335 crossref_primary_10_1016_j_adro_2024_101500 crossref_primary_10_3390_cancers14081934 crossref_primary_10_1007_s12672_023_00613_6 crossref_primary_10_1097_PAS_0000000000002142 crossref_primary_10_1097_PAS_0000000000001055 |
ContentType | Journal Article |
Copyright | 2016 2016 by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology. |
Copyright_xml | – notice: 2016 2016 by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology. |
DBID | CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S PQEST PQQKQ PQUKI PRINS |
DOI | 10.1097/IGC.0000000000000720 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central AUTh Library subscriptions: ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest One Academic ProQuest Central (Alumni) |
DatabaseTitleList | ProQuest One Academic Eastern Edition MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1525-1438 |
EndPage | 1104 |
ExternalDocumentID | 27177280 |
Genre | Journal Article |
GroupedDBID | --- .3N .Z2 0R~ 1OC 29J 31~ 36B 4.4 53G 5GY 5VS 7X7 8-1 8FI 8FJ AAKAS AARTV ABBUW ABJNI ABUWG ABXVJ ABZAD ACDDN ACEWG ACGFO ACGFS ACWDW ACWRI ACXNZ ACXQS ADZCM AENEX AFBPY AFEBI AFKRA AFTRI AFZJQ AGINI AHEFC AIZYK AJAOE AJNYG AJYBZ ALMA_UNASSIGNED_HOLDINGS AWKKM BENPR BFHJK CAG CCPQU CGR CO8 COF CS3 CUY CVF CXRWF DC6 DCZOG E.X EBS ECM EIF EJD EX3 F5P FL- FYUFA FZ0 HAJ HMCUK HZI HZ~ IHE IN~ KD2 L-C LH4 LW6 NPM O9- OCUKA OHYEH ORVUJ OUVQU OVD OXXIT P2P RMJ ROL S4S TEORI UDS UKHRP V2I W3M W99 WOW X3V X3W YUY 3V. 7XB 8FK AAHLL ALIPV K9. PQEST PQQKQ PQUKI PRINS |
ID | FETCH-LOGICAL-c4500-1dc0f5952784fb196df2df1d25b1bbf2aab24d735c99a12b08287b117007d6c13 |
IEDL.DBID | BENPR |
ISSN | 1048-891X |
IngestDate | Fri Sep 13 07:16:58 EDT 2024 Fri May 24 00:02:03 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4500-1dc0f5952784fb196df2df1d25b1bbf2aab24d735c99a12b08287b117007d6c13 |
PMID | 27177280 |
PQID | 2579086671 |
PQPubID | 5161120 |
PageCount | 7 |
ParticipantIDs | proquest_journals_2579086671 pubmed_primary_27177280 |
PublicationCentury | 2000 |
PublicationDate | 2016-07-00 20160701 |
PublicationDateYYYYMMDD | 2016-07-01 |
PublicationDate_xml | – month: 07 year: 2016 text: 2016-07-00 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: Oxford |
PublicationTitle | International journal of gynecological cancer |
PublicationTitleAlternate | Int J Gynecol Cancer |
PublicationYear | 2016 |
Publisher | BMJ Publishing Group LTD |
Publisher_xml | – name: BMJ Publishing Group LTD |
SSID | ssj0009209 |
Score | 2.5332344 |
Snippet | The aim was to study the incidence and survival of patients with uterine sarcoma diagnosed in the period from 2000 to 2012 based on Surveillance, Epidemiology,... ObjectiveThe aim was to study the incidence and survival of patients with uterine sarcoma diagnosed in the period from 2000 to 2012 based on Surveillance,... |
SourceID | proquest pubmed |
SourceType | Aggregation Database Index Database |
StartPage | 1098 |
SubjectTerms | Adult Age Carcinosarcoma - epidemiology Confidence intervals Epidemiology Female Humans Incidence Leiomyosarcoma - epidemiology Proportional Hazards Models Radiation Registries Sarcoma Sarcoma - epidemiology Sarcoma, Endometrial Stromal - epidemiology SEER Program Surgery Surveillance United States - epidemiology Uterine cancer Uterine Neoplasms - epidemiology |
Title | Uterine Sarcoma: Analysis of 13,089 Cases Based on Surveillance, Epidemiology, and End Results Database |
URI | https://www.ncbi.nlm.nih.gov/pubmed/27177280 https://www.proquest.com/docview/2579086671/abstract/ |
Volume | 26 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NT8IwFG_4SIwX47cokh480rB269Z5MYJDNIEQkIQb6cfqRTeEYeJ_b7uPcNIma9LDLv21fa997_1-ANwRRnXMhEA8cCnyNMaIcaaRMNbd05JqmtMXjyf-aOG9LumyBkZVLYxNq6zOxPygVqm0b-Q9s7RC4377Ae5xYV8BZNZ7WH8hqx9l46ylmEYdNAn2bMC22Y8m09megLdI9zC3D4ZYiJdVGV0Y9F6eBwWNYdUC4vztcOaGZ3gMjkqPET4WEJ-AWpycgoNxGRM_A--LLC_hg3OzZtNPfg8rohGYaojdrsNCODDGagv7plcwTeB8t_mOrd6QgbwLo71K7E8X8kTByHyzeLv7yLbwiWfc2rpzsBhGb4MRKuUTkPSo4yCspKNpSG1oUQuz05QmSmNFqMBCaMK5IJ4yEMkw5JiInPteWCUaJ1C-xO4FaCRpEl8B6GutHS4dFijmcR4KL3ZdLaVPMVOYyBZoV7O1KvfAdrVHrAUuixlcrQsKjRUxt0grjHX9_4834NA4KH6RHtsGjWyzi2-NE5CJDqgHy6BTomxGk-n4F54nsIE |
link.rule.ids | 315,786,790,12083,21416,27957,27958,31754,33779,43345,43840,74102,74659 |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV27TsMwFLWgSMCCeFMo4IGxFrFjJw4LgtLSAmUAKnWL_IhZIClNisTfY-ehThAp2bL4XPse-16fA8AF4cwkXEokQp8hajBGXHCDpM3u1ChmWClfPH4OhhP6MGXT-sAtr9sqmzWxXKh1ptwZ-aUNrcjS7yDE17Mv5FyjXHW1ttBYBWvU96lr6Qun4VJ0t2rxsDsOjniEp83VuSi8HN33KunC5gmJ9zfJLJPNYBts1SwR3lSw7oCVJN0F6-O6Dr4H3idFeW0Pvto4zT7FFWzERWBmIPa7Ho9gzyaoHN7ar4ZZCl8X8-_EeQxZmLuwv3SG_elCkWrYt-9Lki8-ihzeiUK4_LYPJoP-W2-IassEpCjzPIS18gyLmCsnGmlnlzZEG6wJk1hKQ4SQhGoLi4oigYks9e6lc5_xQh0o7B-AVpqlyRGAgTHGE8rjoeZUiEjSxPeNUgHDXGOi2qDTjFZcx30eL1Fqg8NqBONZJZsRE7tzdGZYx___eA42hm_jp_hp9Px4AjYtQQmq9tgOaBXzRXJqSUAhz0qkfwHpSqxb |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV27TsMwFLWgSIgF8aZQwANjrdpOnDgsCEpLy0sIqNQt8iNmgaQ0KRJ_j52HOkEkZ_PiY_te-x6fA8A55cwkXEokQo8h3xCCuOAGSRvdfaOYYaV88eNTMJr4d1M2rflPeU2rbPbEcqPWmXJ35D07tSKbfgch6ZmaFvF8M7ycfSHnIOUqrbWdxipYs1ESOzeDcBouBXgruoc9fXDEIzJtntFFYW98269kDJsvpPjvhLMMPMMtsFlnjPCqgngbrCTpDlh_rGviu-B9UpRP-OCrnbPZp7iAjdAIzAwkXhfzCPZtsMrhtf1rmKXwdTH_TpzfkIW8CwdLl9ifLhSphgPbXpJ88VHk8EYUwsW6PTAZDt76I1TbJyDlM4wR0QobFjFXWjTSrjRtqDZEUyaJlIYKIamvLUQqigShstS-l86JBoc6UMTbB600S5NDAANjDBYK81BzX4hI-onnGaUCRrgmVLVBpxmtuF4DebxErA0OqhGMZ5WERkztKdIZYx393_EMrFuQ44fx0_0x2LC5SlAxZTugVcwXyYnNBwp5WgL9C99asIc |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Uterine+Sarcoma%3A+Analysis+of+13%2C089+Cases+Based+on+Surveillance%2C+Epidemiology%2C+and+End+Results+Database&rft.jtitle=International+journal+of+gynecological+cancer&rft.au=Hosh%2C+Mona&rft.au=Antar%2C+Sarah&rft.au=Nazzal%2C+Ahmed&rft.au=Warda%2C+Mahmoud&rft.date=2016-07-01&rft.pub=BMJ+Publishing+Group+LTD&rft.issn=1048-891X&rft.eissn=1525-1438&rft.volume=26&rft.issue=6&rft.spage=1098&rft.epage=1104&rft_id=info:doi/10.1097%2FIGC.0000000000000720&rft.externalDBID=HAS_PDF_LINK |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1048-891X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1048-891X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1048-891X&client=summon |